{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T02:27:08Z","timestamp":1779416828215,"version":"3.53.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"DOI":"10.1007\/s40520-026-03382-8","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T03:49:04Z","timestamp":1775879344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends and prescribing patterns of antiosteoporosis medicines in Chinese patients: a real-world retrospective study"],"prefix":"10.1007","volume":"38","author":[{"given":"Shuo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongning","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"3382_CR1","doi-asserted-by":"publisher","unstructured":"(1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646\u2013650. https:\/\/doi.org\/10.1016\/0002-93439390218-e","DOI":"10.1016\/0002-93439390218-e"},{"key":"3382_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE et al (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513\u2013521.https:\/\/doi.org\/10.1001\/jama.2009.50","journal-title":"JAMA"},{"key":"3382_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00198-005-0015-8","volume":"17","author":"F Borgstr\u00f6m","year":"2006","unstructured":"Borgstr\u00f6m F, Zethraeus N, Johnell O et al (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637\u2013650.https:\/\/doi.org\/10.1007\/s00198-005-0015-8","journal-title":"Osteoporos Int"},{"key":"3382_CR4","doi-asserted-by":"publisher","unstructured":"Lin X, Xiong D, Peng YQ, et al (2015) Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives. Clin Interv Aging 10:1017\u20131033. https:\/\/doi.org\/10.2147\/cia.S54613","DOI":"10.2147\/cia.S54613"},{"key":"3382_CR5","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00198-017-3985-4","volume":"28","author":"NA Mohd-Tahir","year":"2017","unstructured":"Mohd-Tahir NA, Li SC (2017) Economic burden of osteoporosis-related hip fracture in Asia: a systematic review. Osteoporos Int 28:2035\u20132044.https:\/\/doi.org\/10.1007\/s00198-017-3985-4","journal-title":"Osteoporos Int"},{"key":"3382_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-021-02772-0","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N, Ghasemi H, Mohammadi L et al (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16:609.https:\/\/doi.org\/10.1186\/s13018-021-02772-0","journal-title":"J Orthop Surg Res"},{"key":"3382_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41514-025-00269-2","volume":"11","author":"H Liang","year":"2025","unstructured":"Liang H, Chen S, Shi M et al (2025) Global epidemiology and burden of osteoporosis among postmenopausal women: insights from the Global Burden of Disease Study 2021. NPJ Aging 11:78.https:\/\/doi.org\/10.1038\/s41514-025-00269-2","journal-title":"NPJ Aging"},{"key":"3382_CR8","first-page":"317","volume":"2019","author":"Research CSoOaBM","year":"2019","unstructured":"Research CSoOaBM (2019) Results of China\u2019s osteoporosis epidemiological survey and \u201cHealthy Bones\u201d special action plan released. Chinese Journal of Osteoporosis and Bone Mineral Research 2019:317\u2013318","journal-title":"Chinese Journal of Osteoporosis and Bone Mineral Research"},{"key":"3382_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00198-015-3093-2","volume":"26","author":"L Si","year":"2015","unstructured":"Si L, Winzenberg TM, Jiang Q et al (2015) Projection of osteoporosis-related fractures and costs in China: 2010-2050. Osteoporos Int 26:1929\u20131937.https:\/\/doi.org\/10.1007\/s00198-015-3093-2","journal-title":"Osteoporos Int"},{"key":"3382_CR10","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/eje-18-0056","volume":"179","author":"AD Anastasilakis","year":"2018","unstructured":"Anastasilakis AD, Polyzos SA, Makras P (2018) Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol 179:R31-r45.https:\/\/doi.org\/10.1530\/eje-18-0056","journal-title":"Eur J Endocrinol"},{"key":"3382_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11914-021-00663-1","volume":"19","author":"F Cosman","year":"2021","unstructured":"Cosman F, Dempster DW (2021) Anabolic agents for postmenopausal osteoporosis: how do you choose? Curr Osteoporos Rep 19:189\u2013205.https:\/\/doi.org\/10.1007\/s11914-021-00663-1","journal-title":"Curr Osteoporos Rep"},{"key":"3382_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00803","volume":"8","author":"V Pavone","year":"2017","unstructured":"Pavone V, Testa G, Giardina SMC et al (2017) Pharmacological therapy of osteoporosis: a systematic current review of literature. Front Pharmacol 8:803.https:\/\/doi.org\/10.3389\/fphar.2017.00803","journal-title":"Front Pharmacol"},{"key":"3382_CR13","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2024.2252","author":"KJ Kim","year":"2025","unstructured":"Kim KJ, Boo D, Choi J et al (2025) Comprehensive evaluation of treatment patterns in postmenopausal patients with osteoporosis without fractures: insights from tertiary care institutions and nationwide OMOP-CDM data. Endocrinol Metab.https:\/\/doi.org\/10.3803\/EnM.2024.2252","journal-title":"Endocrinol Metab"},{"key":"3382_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116255","volume":"154","author":"B Cortet","year":"2022","unstructured":"Cortet B, Schott AM, D\u00e9sam\u00e9ricq G et al (2022) Trends in postmenopausal osteoporosis treatment in France during the period 2007-2016: a nationwide claims database analysis. Bone 154:116255.https:\/\/doi.org\/10.1016\/j.bone.2021.116255","journal-title":"Bone"},{"key":"3382_CR15","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s11606-021-06938-8","volume":"37","author":"SJ Cromer","year":"2022","unstructured":"Cromer SJ, D\u2019Silva KM, Yu EW et al (2022) Secular trends in the pharmacologic treatment of osteoporosis and malignancy-related bone disease from 2009 to 2020. J Gen Intern Med 37:1917\u20131924.https:\/\/doi.org\/10.1007\/s11606-021-06938-8","journal-title":"J Gen Intern Med"},{"key":"3382_CR16","unstructured":"Center for drug evaluation, NMPA (2025) Denosumab Injection (JXSS2200019) \u2013 Marked Information. Available from: https:\/\/www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=597ef0e4943ab7ee72f315ff8a10b355."},{"key":"3382_CR17","unstructured":"Center for drug evaluation, NMPA (2025) Edible Calcitriol Soft Capsules (JXHS1800012) \u2013 Marked Information. Available from: https:\/\/www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=c9fff209ee91ae4821b5157442312361."},{"key":"3382_CR18","first-page":"1671","volume":"2023","author":"Research CSoOaBM","year":"2023","unstructured":"Research CSoOaBM (2023) Guidelines for the diagnosis and treatment of primary osteoporosis (2022). Chinese General Practice 2023:1671\u20131691","journal-title":"Chinese General Practice"},{"key":"3382_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2024.101778","volume":"21","author":"X Liu","year":"2024","unstructured":"Liu X, Zhu Z, Wang X (2024) Analysis of medication treatment for women with osteoporosis: A real-world retrospective study from Chinese tertiary grade A hospital. Bone Rep 21:101778.https:\/\/doi.org\/10.1016\/j.bonr.2024.101778","journal-title":"Bone Rep"},{"key":"3382_CR20","doi-asserted-by":"publisher","unstructured":"Chen B, Chen L, Yu Z, et al (2025) A retrospective analysis of anti-osteoporosis medication trends among patients under 50 years old in nine major regions of China from 2016 to 2019. Peer J 13:e19187. https:\/\/doi.org\/10.7717\/peerj.19187","DOI":"10.7717\/peerj.19187"},{"key":"3382_CR21","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s00198-021-05951-1","volume":"32","author":"AJ Singer","year":"2021","unstructured":"Singer AJ, Liu J, Yan H et al (2021) Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage. Osteoporos Int 32:2473\u20132484.https:\/\/doi.org\/10.1007\/s00198-021-05951-1","journal-title":"Osteoporos Int"},{"key":"3382_CR22","unstructured":"Fracture Risk Assessment Tool (2025) Available from: https:\/\/frax.shef.ac.uk\/FRAX\/."},{"key":"3382_CR23","doi-asserted-by":"publisher","unstructured":"Morin SN, Feldman S, Funnell L, et al (2023) Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. Cma j 195:E1333-e1348. https:\/\/doi.org\/10.1503\/cmaj.221647","DOI":"10.1503\/cmaj.221647"},{"key":"3382_CR24","doi-asserted-by":"publisher","unstructured":"Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, et al (2023) Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med 176:224\u2013238. https:\/\/doi.org\/10.7326\/m22-1034","DOI":"10.7326\/m22-1034"},{"key":"3382_CR25","doi-asserted-by":"publisher","unstructured":"Fuggle NR, Beaudart C, Bruy\u00e8re O, et al (2024) Evidence-Based Guideline for the management of osteoporosis in men. Nat Rev Rheumatol 20:241\u2013251. https:\/\/doi.org\/10.1038\/s41584-024-01094-9","DOI":"10.1038\/s41584-024-01094-9"},{"key":"3382_CR26","doi-asserted-by":"publisher","unstructured":"Lin SY, Chen YM, Chen WJ, et al (2022) Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan. Arch Osteoporos 17:94. https:\/\/doi.org\/10.1007\/s11657-022-01125-6","DOI":"10.1007\/s11657-022-01125-6"},{"key":"3382_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70008","author":"A Smith","year":"2025","unstructured":"Smith A, Kelly L, Gorry C et al (2025) Utilization and expenditure on medicines for the management of osteoporosis in Ireland: A repeated cross-sectional study. Br J Clin Pharmacol.https:\/\/doi.org\/10.1002\/bcp.70008","journal-title":"Br J Clin Pharmacol"},{"key":"3382_CR28","doi-asserted-by":"publisher","unstructured":"Bone HG, Wagman RB, Brandi ML, et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523. https:\/\/doi.org\/10.1016\/s2213-85871730138-9","DOI":"10.1016\/s2213-85871730138-9"},{"key":"3382_CR29","doi-asserted-by":"publisher","unstructured":"Curtis JR, Arora T, Liu Y, et al (2024) Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis. J Bone Miner Res 39:826\u2013834. https:\/\/doi.org\/10.1093\/jbmr\/zjae079","DOI":"10.1093\/jbmr\/zjae079"},{"key":"3382_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/jbmr\/zjae070","volume":"39","author":"C Park","year":"2024","unstructured":"Park C, Kim C, Park RW et al (2024) Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea. J Bone Miner Res 39:835\u2013843.https:\/\/doi.org\/10.1093\/jbmr\/zjae070","journal-title":"J Bone Miner Res"},{"key":"3382_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.semarthrit.2019.02.007","volume":"49","author":"H Florez","year":"2019","unstructured":"Florez H, Ram\u00edrez J, Monegal A et al (2019) Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature. Semin Arthritis Rheum 49:197\u2013203.https:\/\/doi.org\/10.1016\/j.semarthrit.2019.02.007","journal-title":"Semin Arthritis Rheum"},{"key":"3382_CR32","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.2147\/dddt.S465960","volume":"18","author":"S Huang","year":"2024","unstructured":"Huang S, Li J, Hu X et al (2024) A health technology assessment based on Chinese guideline: active vitamin D and its analogs in the treatment of osteoporosis. Drug Des Devel Ther 18:2593\u20132608.https:\/\/doi.org\/10.2147\/dddt.S465960","journal-title":"Drug Des Devel Ther"},{"key":"3382_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R et al (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344.https:\/\/doi.org\/10.1007\/s00198-018-4704-5","journal-title":"Osteoporos Int"},{"key":"3382_CR34","doi-asserted-by":"publisher","unstructured":"Si L, Tu L, Xie Y, et al (2019) Chinese patients' preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment. Arch Osteoporos 14:85. https:\/\/doi.org\/10.1007\/s11657-019-0624-z","DOI":"10.1007\/s11657-019-0624-z"},{"key":"3382_CR35","doi-asserted-by":"publisher","unstructured":"Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. Bm j 339:b3692. https:\/\/doi.org\/10.1136\/bmj.b3692","DOI":"10.1136\/bmj.b3692"},{"key":"3382_CR36","doi-asserted-by":"publisher","unstructured":"Matsumoto T, Ito M, Hayashi Y, et al (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study. Bone 49:605\u2013612. https:\/\/doi.org\/10.1016\/j.bone.2011.07.011","DOI":"10.1016\/j.bone.2011.07.011"},{"key":"3382_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56297-y","volume":"9","author":"J Wei","year":"2019","unstructured":"Wei J, Zhu A, Ji JS (2019) A comparison study of vitamin D deficiency among older adults in China and the United States. Sci Rep 9:19713.https:\/\/doi.org\/10.1038\/s41598-019-56297-y","journal-title":"Sci Rep"},{"key":"3382_CR38","doi-asserted-by":"publisher","unstructured":"Wang L, Xu X, Zhang M, et al (2023) Prevalence of Chronic Kidney Disease in China: Results From the Sixth China Chronic Disease and Risk Factor Surveillance. JAMA Intern Med 183:298\u2013310. https:\/\/doi.org\/10.1001\/jamainternmed.2022.6817","DOI":"10.1001\/jamainternmed.2022.6817"},{"key":"3382_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00774-012-0397-6","volume":"31","author":"H Hagino","year":"2013","unstructured":"Hagino H, Takano T, Fukunaga M et al (2013) Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis. J Bone Miner Metab 31:183\u2013189.https:\/\/doi.org\/10.1007\/s00774-012-0397-6","journal-title":"J Bone Miner Metab"},{"key":"3382_CR40","first-page":"1209","volume":"36","author":"Guan haijing Xy","year":"2025","unstructured":"Guan haijing Xy (2025) Zhao zhigang, Fan changsheng (2025) Cost-effectiveness of vitamin D analogue for postmenopausal osteoporosis in women. China Pharmacy 36:1209\u20131215","journal-title":"China Pharmacy"},{"key":"3382_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.870277","volume":"13","author":"BR Cheng","year":"2022","unstructured":"Cheng BR, Wu RY, Gao QY et al (2022) Chinese proprietary medicine Xianling Gubao capsule for osteoporosis: A systematic review and meta-analysis of randomized clinical trials. Front Endocrinol (Lausanne) 13:870277.https:\/\/doi.org\/10.3389\/fendo.2022.870277","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3382_CR42","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/os.12439","volume":"11","author":"J Sun","year":"2019","unstructured":"Sun J, Yang XG, Hu YC (2019) Efficacy of Jintiange Capsules in the treatment of osteoporosis: a network meta-analysis. Orthop Surg 11:176\u2013186.https:\/\/doi.org\/10.1111\/os.12439","journal-title":"Orthop Surg"},{"key":"3382_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctcp.2021.101419","volume":"44","author":"J Zhao","year":"2021","unstructured":"Zhao J, Zeng L, Wu M et al (2021) Efficacy of Chinese patent medicine for primary osteoporosis: A network meta-analysis. Complement Ther Clin Pract 44:101419.https:\/\/doi.org\/10.1016\/j.ctcp.2021.101419","journal-title":"Complement Ther Clin Pract"},{"key":"3382_CR44","doi-asserted-by":"publisher","unstructured":"Zhu HM, Qin L, Garnero P, et al (2012) The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis. Osteoporos Int 23:1317\u20131327. https:\/\/doi.org\/10.1007\/s00198-011-1577-2","DOI":"10.1007\/s00198-011-1577-2"},{"key":"3382_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jot.2022.05.002","volume":"35","author":"H Liang","year":"2022","unstructured":"Liang H, Wang O, Cheng Z et al (2022) Jintiange combined with alfacalcidol improves muscle strength and balance in primary osteoporosis: A randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trial. J Orthop Transl 35:53\u201361.https:\/\/doi.org\/10.1016\/j.jot.2022.05.002","journal-title":"J Orthop Transl"},{"key":"3382_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-023-00306-4","volume":"12","author":"YY Zhang","year":"2024","unstructured":"Zhang YY, Xie N, Sun XD et al (2024) Insights and implications of sexual dimorphism in osteoporosis. Bone Res 12:8.https:\/\/doi.org\/10.1038\/s41413-023-00306-4","journal-title":"Bone Res"},{"key":"3382_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278368","volume":"17","author":"G Hoit","year":"2022","unstructured":"Hoit G, Whelan DB, Atrey A et al (2022) Association of age, sex and race with prescription of anti-osteoporosis medications following low-energy hip fracture in a retrospective registry cohort. PLoS ONE 17:e0278368.https:\/\/doi.org\/10.1371\/journal.pone.0278368","journal-title":"PLoS ONE"},{"key":"3382_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-023-04430-y","volume":"23","author":"Q Li","year":"2023","unstructured":"Li Q, Yang J, Tang Q et al (2023) Age-dependent gender differences in the diagnosis and treatment of osteoporosis during hospitalization in patients with fragility fractures. BMC Geriatr 23:728.https:\/\/doi.org\/10.1186\/s12877-023-04430-y","journal-title":"BMC Geriatr"},{"key":"3382_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-021-00932-7","volume":"16","author":"ME Walsh","year":"2021","unstructured":"Walsh ME, Fahey T, Moriarty F (2021) Persistence with oral bisphosphonates and denosumab among older adults in primary care in Ireland. Arch Osteoporos 16:71.https:\/\/doi.org\/10.1007\/s11657-021-00932-7","journal-title":"Arch Osteoporos"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-026-03382-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-026-03382-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-026-03382-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:49:35Z","timestamp":1779414575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-026-03382-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3382"],"URL":"https:\/\/doi.org\/10.1007\/s40520-026-03382-8","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the institutional review board of the Nanjing Medical University (Approval Number: 2025140).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"133"}}